[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Protective effects of ginsenoside Rb1 on human umbilical vein endothelial cells in vitro

J Cardiovasc Pharmacol. 2007 Sep;50(3):314-20. doi: 10.1097/FJC.0b013e3180cab12e.

Abstract

Ginseng has beneficial effects on the cardiovascular system, but its underlying mechanism is unclear. This study investigated the effects of ginsenoside Rb1, a major constituent of ginseng, on the changes of lactate dehydrogenase (LDH) activity, nitric oxide (NO), tissue-type plasminogen activator (t-PA), and plasminogen activator inhibitor-1 (PAI-1) in oxidized low-density lipoprotein (oxLDL)-injuring endothelial cells. Human umbilical vein endothelial cells were cultured and divided into 6 groups (n = 6): control group, oxLDL alone group (100 mg/L), ginsenoside Rb1 alone group (10 microg/mL), oxLDL plus ginsenoside Rb1 groups (0.1, 1.0, and 10 microg/mL, respectively.). Twenty-four hours after treatment, LDH activity and concentrations of NO, t-PA, and PAI-1 in culture medium were measured while the expressions of endothelial nitric oxide synthase (eNOS), t-PA, and PAI-1 mRNA in endothelial cells were detected by reverse-transcriptase polymerase chain reaction. Compared with control group, oxLDL (100 mg/L) caused LDH activity, the expressions of eNOS and t-PA mRNA, and concentrations of NO and t-PA to significantly decrease (P < 0.05, respectively), and it also led to dramatic increase of PAI-1 mRNA and concentration (P < 0.05, respectively). Ginsenoside Rb1 alone did not demonstrate this ability. High-dose Rb1 (10 microg/mL) could block the effects of oxLDL on LDH activity, mRNA of eNOS, t-PA, and PAI-1, and concentrations of NO, t-PA, and PAI-1 (P < 0.05, respectively), and neither low-dose Rb1 (0.1 microg/mL) nor medium-dose Rb1 (1.0 microg/mL) demonstrated this ability. We conclude that ginsenoside Rb1 has protective effects on oxLDL-injuring human vascular endothelial cells and can reverse the effects of oxLDL on NO, t-PA, and PAI-1.

MeSH terms

  • Dose-Response Relationship, Drug
  • Endothelium, Vascular / drug effects*
  • Gene Expression Regulation, Enzymologic / drug effects
  • Ginsenosides / administration & dosage
  • Ginsenosides / pharmacology*
  • Humans
  • L-Lactate Dehydrogenase / drug effects
  • L-Lactate Dehydrogenase / metabolism
  • Lipoproteins, LDL
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type III / drug effects
  • Nitric Oxide Synthase Type III / metabolism
  • Oxidative Stress / drug effects*
  • Plasminogen Activator Inhibitor 1 / metabolism
  • RNA, Messenger / drug effects
  • RNA, Messenger / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tissue Plasminogen Activator / drug effects
  • Tissue Plasminogen Activator / metabolism
  • Umbilical Veins / cytology

Substances

  • Ginsenosides
  • Lipoproteins, LDL
  • Plasminogen Activator Inhibitor 1
  • RNA, Messenger
  • oxidized low density lipoprotein
  • Nitric Oxide
  • ginsenoside Rb1
  • L-Lactate Dehydrogenase
  • Nitric Oxide Synthase Type III
  • Tissue Plasminogen Activator